

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺 诚 健 华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9969)

VOLUNTARY ANNOUNCEMENT

POSITIVE TOPLINE RESULTS FROM THE PHASE II PORTION OF THE PHASE II/III ADAPTIVE STUDY OF SOFICITINIB (ICP-332) IN NON-SEGMENTAL VITILIGO

This announcement is made by InnoCare Pharma Limited (the “**Company**”) on a voluntary basis to inform shareholders and potential investors of the Company’s latest business developments.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Phase II portion of the ongoing Phase II/III adaptive clinical study of soficitinib (ICP-332), the Company’s internally discovered and developed next-generation oral tyrosine kinase 2 (“**TYK2**”) inhibitor, in adult patients with non-segmental vitiligo has successfully met its primary endpoint.

Study Design

The ongoing study is a Phase II/III randomized, double-blind, placebo-controlled, parallel-group, adaptive, multicenter clinical study designed to evaluate the efficacy and safety of soficitinib (ICP-332) in patients with non-segmental vitiligo.

The study consists of a Phase II portion followed by a Phase III portion. This announcement relates to the top-line results from the Phase II portion.

Phase II Topline Results

The Phase II portion met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements versus placebo at Week 24. Treatment with soficitinib (ICP-332) also demonstrated consistent efficacy across multiple secondary endpoints.

At Week 24, treatment with soficitinib (ICP-332) resulted in significant improvements from baseline in Facial Vitiligo Area Scoring Index (F-VASI). The least-squares mean percent change from baseline in F-VASI was 38.8% in the 80 mg once-daily group and 41.2% in the 120 mg once-daily group, compared with 2.2% in the placebo group. Both soficitinib (ICP-332) dose groups demonstrated statistically significant improvements versus placebo ($P < 0.0001$).

The safety profile of soficitinib (ICP-332) was consistent with previous clinical studies. The treatment was well tolerated, and no new safety signals were identified.

Detailed efficacy and safety results from the Phase II portion will be presented at upcoming international scientific congresses and submitted for publication in a peer-reviewed medical journal.

The ongoing Phase II/III adaptive study will continue in accordance with the study protocol. The Company plans to discuss the Phase II results with regulatory authorities and continue advancing the clinical development of soficitinib (ICP-332) in non-segmental vitiligo.

About Non-segmental Vitiligo

Non-segmental vitiligo is a chronic autoimmune skin disorder characterized by progressive depigmentation resulting from the loss of functional melanocytes. The disease can substantially affect patients' appearance, emotional well-being and quality of life. Although treatment options have expanded in recent years, there remains a need for effective and well-tolerated systemic therapies for patients with moderate-to-severe disease.

About Soficitinib (ICP-332)

Soficitinib (ICP-332) is a next-generation, highly selective oral TYK2 inhibitor discovered and developed by the Company. TYK2 is a member of the JAK family and plays a critical role in transducing signals downstream of IL-12/IL-23 family interleukin receptors as well as type I interferon receptor. These cytokine/receptor pathways regulate the activity of T helper 17, T helper 1, B and myeloid cells, which are critical in the pathobiology of multiple autoimmune and chronic inflammatory diseases including psoriasis, inflammatory bowel disease, lupus, atopic dermatitis, etc. Soficitinib (ICP-332) was designed to be a potent and selective TYK2 inhibitor with 400-fold selectivity against JAK2 with the aim of minimizing adverse events associated with nonselective JAK inhibitors. Thus, by selective inhibition

of TYK2, soficitinib (ICP-332) has the potential to provide meaningful therapeutic benefit for multiple autoimmune diseases with a potentially favorable safety profile. As of the date of this announcement, soficitinib (ICP-332) is being evaluated across five autoimmune indications, including atopic dermatitis, vitiligo, prurigo nodularis, chronic spontaneous urticaria and psoriasis, with multiple clinical data readouts expected.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize soficitinib (ICP-332) for the treatment of vitiligo successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 16 July 2026

As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.